N,N-diethyl 4-tert-butyl-2-hydroxybenzamide | 698377-42-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-diethyl 4-tert-butyl-2-hydroxybenzamide
• 英文别名: 5-(tert-butyl)-N,N-diethyl-2-hydroxybenzamide；N,N-diethyl-5-tert-butyl-2-hydroxybenzamide；5-tert-butyl-N,N-diethyl-2-hydroxybenzamide
• CAS: 698377-42-3
• 化学式: C₁₅H₂₃NO₂
• 分子量: 249.353
• InChiKey: KINDQSAHRLPQMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-diethyl 4-tert-butyl-2-hydroxybenzamide 在 RuH₂(CO)(PPh₃)₃ 、 potassium carbonate 作用下， 以 丙酮 、 甲苯 为溶剂， 反应 20.0h， 生成 N,N-diethyl-5-tert-butyl-2-(4-methoxyphenyl)benzamide
  参考文献：
  名称：

  超越定向正金属化：Ru 催化的 CAr-O 活化/酰胺螯合的交叉偶联反应

  摘要：

  公开了一种通过邻甲氧基苯甲酰胺与芳基硼戊酸酯的交叉偶联化学合成联芳基、杂联芳基和聚芳基分子的新的、催化的和通用的方法。该反应基于使用催化 RuH2(CO)(PPh3)3 条件通过邻近的酰胺导向基团激活非反应性 C-OMe 键。由此建立了一步、无碱偶联过程，它有可能取代有用的两步定向邻位金属化/交叉偶联反应，包括低温和强碱条件。高区域选择性、与 Suzuki-Miyaura 反应的正交性、操作简单、浪费最少和方便的放大使这些反应适合工业应用。

  DOI：

  10.1021/ja503819x
• 作为产物：
  描述：

  (4-叔-丁基苯基) N,N-二乙基氨基甲酸酯 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 N,N-diethyl 4-tert-butyl-2-hydroxybenzamide
  参考文献：
  名称：

  超越定向正金属化：Ru 催化的 CAr-O 活化/酰胺螯合的交叉偶联反应

  摘要：

  公开了一种通过邻甲氧基苯甲酰胺与芳基硼戊酸酯的交叉偶联化学合成联芳基、杂联芳基和聚芳基分子的新的、催化的和通用的方法。该反应基于使用催化 RuH2(CO)(PPh3)3 条件通过邻近的酰胺导向基团激活非反应性 C-OMe 键。由此建立了一步、无碱偶联过程，它有可能取代有用的两步定向邻位金属化/交叉偶联反应，包括低温和强碱条件。高区域选择性、与 Suzuki-Miyaura 反应的正交性、操作简单、浪费最少和方便的放大使这些反应适合工业应用。

  DOI：

  10.1021/ja503819x

文献信息

• Regiospecific synthesis of alkylphenanthrenes using a combined directed <i>ortho</i> and remote metalation – Suzuki–Miyaura cross coupling strategy
  作者：Xiongwei Cai、Stephen Brown、Peter Hodson、Victor Snieckus

  DOI：10.1139/v03-179

  日期：2004.2.1

  Using a combined directed ortho metalation (DoM) – Suzuki–Miyaura cross coupling – directed remote metalation (DreM) approach, the alkylphenanthrenes (APs) 1-methyl- (5a), 1,7-dimethyl- (5b), 2,7-dimethyl- (5c), 7-ethyl-1-methyl- (15), and 7-tert-butyl-1-methylphenanthrenes (27) have been synthesized in four to seven steps and 21%–36% overall yields. In contrast to classical protocols, this method, which may be scaled to gram quantities, provides single isomers of APs in high purity of value as analytical standards for environmental studies. Aminocarbonylation of triflates to N,N-diethylbenzamides (9 [Formula: see text] 10) and anionic Fries rearrangement (23 [Formula: see text] 24) provide other potential links to DoM chemistry.Key words: phenanthrene, directed ortho metalation, Suzuki–Miyaura cross coupling, synthesis, polycyclic aromatic hydrocarbon, carbonylation.

  利用结合的定向正金属化（DoM）-Suzuki-Miyaura交叉偶联-定向远程金属化（DreM）方法，已合成了烷基菲（APs）1-甲基-（5a）、1,7-二甲基-（5b）、2,7-二甲基-（5c）、7-乙基-1-甲基-（15）和7-叔丁基-1-甲基菲（27），在四到七个步骤中产率为21%-36%。与传统方法相比，这种方法可以扩展到克量级，提供高纯度的APs单异构体，可用作环境研究的分析标准。三氟甲磺酸酯的氨基羰化反应生成N,N-二乙基苯甲酰胺（9至10），以及阴离子Fries重排反应（23至24）提供了DoM化学的其他潜在联系。关键词：菲、定向正金属化、Suzuki-Miyaura交叉偶联、合成、多环芳烃、羰化。
• DIHYDROXYPHENYL ISOINDOLYLMETHANONES
  申请人：Chessari Gianni

  公开号：US20070259886A1

  公开（公告）日：2007-11-08

  Compounds having the formula (I): and in particular, those of subgenus VIIa are disclosed as inhibits or modulators of the activity of the heat shock protein Hsp90. As such they are useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate cancer, lung cancer, gastrointestinal stromal tumor, breast cancer and melanoma.

  具有公式(I)的化合物，特别是VIIa亚属的化合物，被披露为热休克蛋白Hsp90的抑制剂或调节剂。因此，它们可用于治疗癌症，特别是淋巴或骨髓系的造血肿瘤、前列腺癌、肺癌、胃肠间质瘤、乳腺癌和黑色素瘤。
• Pharmaceutical Compounds
  申请人：Chessari Gianni

  公开号：US20080306054A1

  公开（公告）日：2008-12-11

  The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R 1 is hydroxy or hydrogen; R 2 is hydroxy; methoxy or hydrogen; provided that at least one of R 1 and R 2 is hydroxy; R 3 is selected from hydrogen; halogen; cyano; C 1-5 hydrocarbyl and C 1-5 hydrocarbyloxy; wherein the C 1-5 hydrocarbyl and C 1-5 hydrocarbyloxy moieties are each optionally substituted by one or more substituents selected from hydroxy, halogen, C 1-2 alkoxy, amino, mono- and di-C 1-2 alkylamino, and aryl and heteroaryl groups of 5 to 12 ring members; R 4 is selected from hydrogen; a group —(O) n —R 7 where n is 0 or 1 and R 7 is an acyclic C 1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and mono- or di-C 1-5 hydrocarbyl-amino, wherein the acyclic C 1-5 hydrocarbyl group and the mono and di-C 1-5 hydrocarbylamino moieties in each instance are optionally substituted by one or more substituents selected from hydroxy, halogen, C 1-2 alkoxy, amino, mono- and di-C 1-2 alkylamino, and aryl and heteroaryl groups of 5 to 12 ring members; or R 3 and R 4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and R 5 and R 6 are as defined in the claims.

  本发明提供了一种化合物，用作Hsp90的抑制剂，该化合物具有以下式子（I）或其盐，互变异构体，溶剂合物和N-氧化物；其中，R1是羟基或氢基；R2是羟基，甲氧基或氢基；只要R1和R2中至少有一个是羟基；R3选自氢基，卤素，氰基，C1-5烃基和C1-5烃氧基；其中C1-5烃基和C1-5烃氧基基团均可选择地被一个或多个取代基所取代，所述取代基选自羟基，卤素，C1-2烷氧基，氨基，单烷基和双C1-2烷基氨基以及5至12个环成员的芳基和杂环芳基；R4选自氢基，—（O）n—R7基团，其中n为0或1，R7是一个无环C1-5烃基基团或一个具有3至7个环成员的单环碳环或杂环基团；卤素，氰基，羟基，氨基和单烷基或双C1-5烃基氨基，其中在每种情况下，无环C1-5烃基基团和单烷基和双C1-5烃基氨基基团可选择地被一个或多个取代基所取代，所述取代基选自羟基，卤素，C1-2烷氧基，氨基，单烷基和双C1-2烷基氨基以及5至12个环成员的芳基和杂环芳基；或R3和R4共同形成一个具有5至7个环成员的单环碳环或杂环基团；R5和R6如权利要求所定义。
• Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency
  作者：Christopher W. Murray、Maria G. Carr、Owen Callaghan、Gianni Chessari、Miles Congreve、Suzanna Cowan、Joseph E. Coyle、Robert Downham、Eva Figueroa、Martyn Frederickson、Brent Graham、Rachel McMenamin、M. Alistair O’Brien、Sahil Patel、Theresa R. Phillips、Glyn Williams、Andrew J. Woodhead、Alison J.-A. Woolford

  DOI：10.1021/jm100059d

  日期：2010.8.26

  Inhibitors of the chaperone Hsp90 are potentially useful as chemotherapeutic agents in cancer. This paper describes an application of fragment screening to Hsp90 using a combination of NMR and high throughput X-ray crystallography. The screening identified an aminopyrimidine with affinity in the high micromolar range and subsequent structure-based design allowed its optimization into a low nanomolar series with good ligand efficiency. A phenolic chemotype was also identified in fragment screening and was found to bind with affinity close to 1 mM. This fragment was optimized using structure based design into a resorcinol lead which has subnanomolar affinity for Hsp90, excellent cell potency, and good ligand efficiency. This fragment to lead campaign improved affinity for Hsp90 by over 1,000,000-fold with the addition of only six heavy atoms. The companion paper (DOI: 10.1021/jm100060b) describes how the resorcinol lead was optimized into a compound that is now in clinical trials for the treatment of cancer.
• HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90
  申请人：Astex Therapeutics Limited

  公开号：EP1883402A2

  公开（公告）日：2008-02-06